Wayne, PA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, today announced that it will be expanding its operations in the U.S. with the opening of a new office in Wayne, PA. The expansion marks a key milestone in CluePoints’ ambitious growth strategy that will see the company build its infrastructure to support its rapidly growing U.S. client base.
CluePoints, which already provides its solutions to seven of the top ten global biopharmaceutical companies and notable CROs and medical device companies, has seen demand for its services increase, fueled by growing industry and regulatory recognition of the benefits of a centralized statistical monitoring (CSM) approach. As a result, CluePoints has already grown its U.S. commercial team with the appointment of two new business development executives, and over the next 12 months the company will increase its staff by 50%.
CluePoints’ U.S. operations are being led by Steve Young, chief operations officer, who will be supported by project managers and data analysts at the new office. Their focus will be on developing and supporting both existing and new customers in the region, from small and mid-size organizations to large pharmaceutical companies and CROs.
“A strong presence in the U.S. is a critical next step in our strategy, following momentous growth in demand for our solutions. Not only are our customers experiencing significant tangible cost benefits but industry regulations, especially the imminent revised ICH E6 (R2) GCP guidance, now insist that sponsors have a central statistical approach to driving data quality, integrity and oversight,” comments Steve Young. “We chose Wayne, PA for our operations because it is located within a key region for biotech, CRO, pharma and technology companies, and provides access to a rich talent pool to support our continuing growth.”
For further information on CluePoints’ solutions, please visit www.cluepoints.com
About CluePoints
CluePoints® is a Risk-Based Monitoring and Central Statistical Monitoring solution that has been designed and perfected over the last 15 years. It employs unique statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the ICH, FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring, medical review and to drive a Risk-Based Monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
Media contact
Patrick Hughes – Chief Commercial Officer, CluePoints
[email protected]
+44 (0) 7703 532 749
